United States Patent 7,799,897 Scope and Claims Analysis: (4,12; 7,15) Cyclic Peptide Guanylate Cyclase Agonists and cGMP-Inducing Pharmaceutical Compositions
Executive summary: US 7,799,897 claims a specific guanylate cyclase receptor agonist peptide defined by SEQ ID NO:8 and a structural constraint that the peptide is a (4,12; 7,15) bicycle. Claim scope is anchored to (i) sequence identity to SEQ ID NO:8, (ii) the bicycle topology defined by the (4,12; 7,15) cyclization pattern, and (iii) a functional activity: binding a guanylate cyclase receptor and inducing cGMP production. Dependent claims broaden coverage to pharmaceutical compositions in unit dose forms (including tablets, capsules, solutions, and inhalation formulations) and composition augmentations with selected pharmacological add-ons (cGMP-dependent phosphodiesterase inhibitors, anti-inflammatory, antiviral, anticancer agents). The estate’s enforceability and design-around exposure depend on whether competitors can avoid at least one of the three claim pillars: SEQ ID NO:8 identity, the bicycle topology, or the claimed activity profile as used to meet the “binds… and induces cGMP production” limitation.
What exactly is claimed in US 7,799,897 (scope, sequence dependence, and functional limitations)?
Core claim subject matter:
US 7,799,897 is structured as a classic peptide + composition patent:
- Claim 1: A peptide defined by SEQ ID NO:8, having a (4,12; 7,15) bicycle topology, that binds a guanylate cyclase receptor and induces cGMP production.
- Claim 2: A unit-dose pharmaceutical composition comprising the peptide of claim 1 plus a pharmaceutically acceptable carrier; same bicycle and functional binding/cGMP limitations.
- Claim 3: Same composition of claim 2, with unit dose form constrained to tablet, capsule, solution, or inhalation formulation.
- Claim 4: Same composition of claim 2, with optional additional active components selected from a defined list (PDE inhibitors, anti-inflammatory, antiviral, anticancer).
Claim 1 breakdown: peptide identity + topology + receptor/cGMP functional performance
Claim 1 requires all three limitations simultaneously:
-
Sequence: “A peptide consisting of SEQ ID NO:8”
- This is a closed formulation of the peptide sequence. “Consisting of” typically bars additional residues beyond the SEQ ID NO:8 definition, unless the claim construction allows substitutions that still meet the SEQ ID NO definition (usually it does not).
- Practical implication: a competitor that uses a different sequence, even if it is highly homologous, is outside literal scope.
- A competitor using SEQ ID NO:8 but changing anything that makes the sequence non-identical also risks non-infringement.
-
Topology: “a (4,12; 7,15) bicycle”
- This is a structural constraint that narrows the claimed form even if a competitor uses SEQ ID NO:8.
- The numbering (4,12) and (7,15) implies two cyclization links forming a bicyclic constrained peptide. If a competitor makes a different cyclization pattern (single ring, different bridging positions, linear peptide, or a different bicycle topology), it should be outside the bicycle limitation.
-
Function: “binds a guanylate cyclase receptor and induces cGMP production”
- This is a performance-based limitation. It may be used both for infringement and validity arguments.
- The claim does not specify the disease indication, dose, duration, or assay method. It requires receptor binding and cGMP induction in some functional sense.
Infringement posture implied by Claim 1:
To infringe, the accused product should contain a peptide that is (i) SEQ ID NO:8, (ii) bicycled in the (4,12; 7,15) pattern, and (iii) binds a guanylate cyclase receptor and induces cGMP.
Claim 2 breakdown: unit-dose composition with carrier (no excipient specificity)
Claim 2 adds a composition scaffold:
- A “pharmaceutical composition in unit dose form”
- comprising:
- the SEQ ID NO:8 bicycle peptide
- plus a pharmaceutically acceptable carrier
Carrier language is broad: it captures essentially any standard pharmaceutical carrier/excipient used for oral, injectable, or inhaled dosing, provided it is pharmaceutically acceptable.
No route of administration is included in Claim 2. Route is addressed via Claim 3’s selected unit dose forms.
Claim 3 breakdown: dosage form carve-in
Claim 3 limits the unit dose form to:
- tablet
- capsule
- solution
- inhalation formulation
Implication: if a competitor uses the peptide in another unit dose form (example: powder for insufflation, suppository, prefilled syringe formulation), Claim 3 would not capture that dosage form, though Claim 2 may still capture a “unit dose form” if it is argued to be within the general meaning of unit dose.
Claim 4 breakdown: combination therapy augmentation
Claim 4 expands Claim 2 by adding at least one compound from:
- cGMP-dependent phosphodiesterase inhibitor
- anti-inflammatory agent
- antiviral agent
- anticancer agent
Key scope note: Claim 4 does not specify which molecules in those classes. That creates broad coverage for combination regimens as long as the peptide and carrier structure of Claim 2 remain present.
How broad is SEQ ID NO:8 coverage versus bicycle-structure coverage?
High-level conclusion: Claim scope is narrowest on sequence and topology and broadest on composition carriers and combination class add-ons.
Sequence gating effect (SEQ ID NO:8 “consisting of”)
- The “consisting of SEQ ID NO:8” language is typically the strongest scope limiter.
- It prevents capture of peptides that are:
- sequence variants
- cyclization variants with changed residues
- truncated fragments that are still biologically active
Topology gating effect ((4,12; 7,15) bicycle)
- Even if competitors keep the same sequence, changing cyclization connectivity can avoid literal infringement.
- The topology is not described in claim text beyond the bridge positions, so an infringement analysis in litigation would likely require:
- a mapping of ring-closure chemistry to residue positions (4,12) and (7,15)
- characterization evidence on whether the peptide matches the bicycle topology.
Functional gating effect (binding + cGMP induction)
- A peptide that binds a guanylate cyclase receptor but fails to induce cGMP (or does so through an indirect pathway the patentee tries to distinguish) could be argued out.
- Conversely, a peptide with receptor binding but weaker cGMP induction could still be captured if it measurably “induces cGMP production.”
Net effect: The strongest design-around lever is altering the peptide sequence away from SEQ ID NO:8 or altering the bicycle topology away from (4,12; 7,15).
What are the practical claim construction pressure points in infringement of US 7,799,897?
1) Does the claim cover only one guanylate cyclase receptor subtype?
The claim says “a guanylate cyclase receptor” generically. Unless the specification limits it, the claim may be construed to cover any relevant guanylate cyclase receptor recognized in the context of the patent.
Pressure point: competitors may argue the patentee’s disclosure ties the function to a particular receptor subtype, effectively narrowing “guanylate cyclase receptor” to that disclosed subtype under claim construction principles that incorporate specification.
2) How is “induces cGMP production” evidenced?
The claims do not define:
- the cell type
- the assay
- the magnitude threshold
- whether induction must be direct
Pressure point: In litigation, claim construction may import assay methodology from the specification or prosecution history, limiting how “induces” is measured. The functional limitation may also be used in non-infringement by showing that the accused peptide does not meet the required cGMP effect under the relevant assay conditions.
3) Bicycle definition: what chemistry proves (4,12; 7,15)?
Because claim text depends on residue numbering, infringement often turns on:
- how residues are numbered in the synthetic construct
- whether modifications are present that shift numbering
- whether the bicyclic constraint is actually formed
A peptide with the same functional binding but with a different cyclization topology could be outside the claim even if sequence identity is maintained.
What patent landscape typically surrounds a guanylate cyclase agonist bicyclic peptide like this?
Without external bibliographic and prosecution data, the landscape can only be characterized structurally based on claim architecture and standard peptide IP strategies.
Likely surrounding US patent families and claim categories
A peptide “consisting of SEQ ID NO:X” + “bicycle (i,j; k,l)” claim set generally sits inside a family that can include:
-
Sequence-definition patents
- Multiple SEQ ID NO sequences and analogs, each with bicycling patterns and functional binding/cGMP claims.
-
Topology-specific variants
- Claims to the same SEQ ID but with alternate bridge positions or alternate cyclization geometry (monocycle or different bicyclic pattern).
-
Method-of-use patents
- Indications tied to cGMP signaling (example: pulmonary hypertension, erectile dysfunction, cardiovascular disorders, inflammatory airway disease) with dosing regimens, endpoints, and patient selection.
-
Formulation and delivery patents
- Inhalation formulation scaffolds to stabilize peptide structure and improve deposition.
- Penetration enhancers and aerosolization-compatible excipients.
-
Combination therapy patents
- Pairing with PDE inhibitors or anti-inflammatory/antiviral/anticancer agents.
Business implication: US 7,799,897 most directly covers the molecule and compositions with unit dose forms and certain combination add-ons. If a competitor designs around the bicycle topology, they may still face method-of-use and formulation patents unless those also track the same molecule definition.
What are the key “design-around” options given these claims?
Design-around strategy A: change the peptide sequence (avoid SEQ ID NO:8)
- Keep guanylate cyclase binding and cGMP induction, but alter the sequence.
- Risk: equivalents arguments can arise, but “consisting of SEQ ID NO:8” reduces literal equivalents reach.
Design-around strategy B: keep SEQ ID NO:8 but change cyclization connectivity
- Modify cyclization so it is not a (4,12; 7,15) bicycle.
- Risk: if chemistry still maps to the same (4,12; 7,15) bridge pattern under claim construction, infringement remains.
Design-around strategy C: retain the peptide but switch dosage form
- If the competitor uses a dosage form not covered by Claim 3 (example: injectable unit dose), Claim 3 is avoided, but Claim 2 may still apply if the product is still “unit dose form” with a pharmaceutically acceptable carrier.
- This is a weaker design-around than sequence or topology.
Design-around strategy D: avoid combination add-ons
- Claim 4 adds optional combination components, so avoiding those combinations can avoid Claim 4 specifically.
- Claims 1 to 3 still capture monotherapy.
How does unit dose form language affect market entry and labeling strategies?
Claim 3 constrains the unit dose form set to tablets, capsules, solutions, or inhalation formulations. This affects:
- inhalation strategy: inhalation formulations are explicitly within scope, increasing risk for competitors pursuing pulmonary delivery.
- oral solid strategy: tablet/capsule also in-scope.
- non-enumerated forms: alternative unit-dose forms may reduce Claim 3 coverage, but not necessarily Claim 2.
For a competitor, the safest path is avoiding the molecule definition (SEQ ID NO:8 bicycled at (4,12; 7,15)) rather than relying on dosage form selection.
Which claim covers combination products with PDE inhibitors, anti-inflammatories, antivirals, or anticancer agents?
- Claim 4 is the combination claim, limited to products that meet Claim 2’s structure and then add “at least one compound” from the listed categories.
Coverage implication:
- A monotherapy with the peptide is covered by Claims 1 to 3.
- A combination with any of those categories is covered by Claim 4 as well, provided all underlying limitations are met.
What does this claim set suggest about regulatory and exclusivity interactions?
US patent coverage over a peptide composition can intersect with FDA exclusivity through:
- Drug approval pathway (505(b)(1), 505(b)(2), or 505(j) for generic submissions)
- Orphan or other exclusivity (if applicable)
- 3-year/5-year exclusivity where new clinical studies or new drug-like features are involved
However, the claims themselves do not specify FDA indications or approval status. Their scope is composition and peptide-related. The strongest practical regulatory relevance is whether FDA labeling and development plans require the exact claimed peptide structure and dosage forms.
Key takeaways
- US 7,799,897 Claim 1 is built around a three-part limitation stack: SEQ ID NO:8 identity, a (4,12; 7,15) bicycle topology, and functional activity (guanylate cyclase binding and cGMP production).
- Composition coverage (Claims 2 to 4) is broad on carriers and narrow on unit dose forms (Claim 3) and combination class additions (Claim 4).
- Most effective design-arounds are those that break at least one pillar: change the peptide sequence away from SEQ ID NO:8 or change the bicycle topology away from (4,12; 7,15).
- Dosage form changes can partially shift risk between Claim 3 and Claim 2, but they do not remove coverage for monotherapy under Claims 1 and 2 if the peptide definition remains met.
- Combination products are expressly within scope when paired with PDE inhibitors or anti-inflammatory/antiviral/anticancer agents, under Claim 4.
FAQs
1) Do US 7,799,897 claims require a specific guanylate cyclase receptor subtype or are they generic?
The claim language is generic (“a guanylate cyclase receptor”), so scope depends on how the specification defines the receptor in context.
2) Can a competitor avoid infringement by using a different dosage form than tablet, capsule, solution, or inhalation?
Claim 3 excludes those specific forms, but Claim 2 can still cover “unit dose form” compositions using the same peptide and carrier.
3) Is avoiding the combination partner enough to escape infringement under US 7,799,897?
Avoiding listed combination categories avoids Claim 4, but monotherapy remains covered by Claims 1 to 3 if the peptide definition is met.
4) What matters more for design-around: sequence or bicycle topology?
Both are critical. Changing sequence away from SEQ ID NO:8 and changing cyclization away from the (4,12; 7,15) bicycle are the strongest levers.
5) How is “induces cGMP production” likely to be litigated?
Expect a dispute focused on assay evidence and whether the accused peptide meets the functional induction requirement under relevant conditions.
References (APA)
- United States Patent No. 7,799,897.
